Cellectis S.A.
NASDAQ:CLLS · NASDAQ Global Market
-$0.02 today
Vol 0.16M · Avg 0.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-89.1%
avg -47.9%
ROIC
-16.7%
avg -26.3%
ROA
-20.8%
avg -21.9%
Analysis
ROIC is currently the strongest return metric at -16.7% versus its period average of -26.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Andre Choulika | Co-Founder, Chief Executive Officer & Director | $982,873.00 | — | 61 | — | — |
David J. Sourdive | Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director | $636,274.00 | — | 59 | — | — |
Jean Charles Epinat | Chief Technological Officer | — | — | — | — | — |
Stephan Reynier | Chief Regulatory & Pharmaceutical Compliance Officer | — | — | 57 | — | — |
Kyung Nam-Wortman | Executive Vice President & Chief Human Resources Officer | — | — | 56 | — | — |
Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors | — | — | 44 | — | — |
Pascalyne Wilson | Director of Communications | — | — | — | — | — |
Valerie Cros | Principal Financial Officer & Principal Accounting Officer | — | — | — | — | — |
Philippe Duchateau | Chief Scientific Officer | — | — | 63 | — | — |
Arthur Stril | Chief Financial Officer & Chief Business Officer | — | — | 37 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +25.5% | +7.4% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +25.5% over three years. Forward estimates point to Revenue at +7.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$867.13M
Alto Neuroscience, Inc.
NYSE:ANRO
$783.30M
DBV Technologies S.A.
NASDAQ:DBVT
$382.75M
Amarin Corporation plc
NASDAQ:AMRN
$333.20M
Silence Therapeutics plc
NASDAQ:SLN
$327.10M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$305.94M
AC Immune S.A.
NASDAQ:ACIU
$241.71M
Korro Bio, Inc.
NASDAQ:KRRO
$128.40M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.32M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.02M
Who manages CLLS?
Cellectis S.A. (CLLS) lists 10 active executives. The top listed executive is Jean Charles Epinat, Chief Technological Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.